In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Diamond-Forrester risk model and chest pain typicality in assessment of stable coronary artery disease

Session Poster session 1

Speaker Kenneth Chan

Event : ESC Congress 2017

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease (Chronic)
  • Session type : Poster Session

Authors : K Chan (Oxford,GB), R Sarwar (Oxford,GB)

Authors:
K. Chan1 , R. Sarwar1 , 1Oxford University Hospitals NHS Trust - Oxford - United Kingdom ,

Citation:
European Heart Journal ( 2017 ) 38 ( Supplement ), 198-199

Background: American and European guidelines recommended using Diamond-Forrester risk model (DFRM) to assess stable chest pain by classifying the nature of the chest pain, and then apply a risk model to predict the probability of obstructive coronary artery disease (CAD), although this has been criticised for overestimating the risk of CAD.

Purpose: To study the performance of chest pain typicality in diagnosing CAD in contemporary studies which assessed DFRM.

Methods: We performed a systematic literature search on studies published on MEDLINE and EMBASE until Nov 2016. Searched terms were “Diamond Forrester” and “coronary artery disease”. Overlapping studies and review articles were excluded. Data on the nature of chest pain and presence of CAD was independently extracted by both authors. Crude relative risks (RR) of CAD were calculated by comparing “typical angina” and “atypical angina” respectively to “non-anginal chest pain” or “pain free” as the reference, and not taking into account demographics or cardiovascular risk factors.

Results: 10 studies (n=31,528) were eligible for analysis (mean age 59±10, 54% male). Compared to the original DFRM (NEJM, 1979), more recent studies tended to use cohorts that had more patients with “atypical angina” and “non-anginal chest pain”. Positive diagnoses of CAD also varied significantly (9–88%) in those with “typical angina”. (Table 1) Strikingly those with “atypical chest pain” had similar crude RR of CAD 1.1 (range 0.5–1.9) compared to non-anginal pain.

Conclusions: Many of the contemporary studies assessing the DFRM constitute a lower risk cohort and we opine that classification of the nature of chest pain in several of them was very different to that used in the DFRM, which might explain why DFRM overestimates CAD risk in the contemporary studies.

Table 1. Dramatic variation in the nature of chest pain in contemporary studies and association with CAD (DFRM, Diamond-Forrester risk model)
Nature of chest pain% of patients in group (range)% of patients with obstructive CAD (range)Crude relative risk of CAD (range)
DFRM (n=4952)Contemporary studies (n=31,528)DFRM (n=4952)Contemporary studies (n=31,528)DFRMContemporary studies
typical angina43%14% (7–53%)89%27% (9–88%)5.61.7 (1.1–3.0)
atypical angina39%41% (15–87%)50%14% (9–72%)3.11.1 (0.5–1.9)
non-anginal chest pain18%30% (11–66%)16%22% (8–53%)11

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are